Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJul 05, 2026
DataAggregated Company Financials
Companies182
  • 7D3.3%
  • 3M20.5%
  • 1Y12.6%
  • YTD15.9%

Over the last 7 days, the Pharma industry has risen 3.3%, driven by gains from Sun Pharmaceutical Industries of 2.3%. During this same period, the Rubicon Research underperformed, falling 7.7%. In the last 12 months, the industry was up 13%. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 05 Jul 2026₹23.7t₹4.5t₹643.1b30.1x36.8x5.3x
Tue, 02 Jun 2026₹22.1t₹4.5t₹642.7b28.6x34.4x4.9x
Thu, 30 Apr 2026₹21.0t₹4.3t₹621.1b28.8x33.8x4.8x
Sat, 28 Mar 2026₹20.1t₹4.3t₹621.2b25.1x32.4x4.6x
Mon, 23 Feb 2026₹20.0t₹4.3t₹620.8b26.5x32.3x4.6x
Wed, 21 Jan 2026₹19.5t₹4.2t₹613.7b27.6x31.8x4.6x
Fri, 19 Dec 2025₹20.3t₹4.2t₹614.4b28.1x33.1x4.8x
Sun, 16 Nov 2025₹20.5t₹4.2t₹614.2b29.3x33.4x4.9x
Tue, 14 Oct 2025₹20.2t₹4.1t₹588.2b30.7x34.3x5x
Thu, 11 Sep 2025₹20.5t₹4.1t₹589.1b31.2x34.7x5x
Sat, 09 Aug 2025₹19.8t₹4.0t₹592.7b32.6x33.4x4.9x
Mon, 07 Jul 2025₹20.6t₹4.0t₹595.4b33.8x34.6x5.2x
Wed, 04 Jun 2025₹19.9t₹4.0t₹595.3b33.2x33.4x5x
Fri, 02 May 2025₹19.7t₹3.9t₹562.1b28.8x35x5.1x
Sun, 30 Mar 2025₹19.4t₹3.9t₹559.4b29.7x34.7x5x
Tue, 25 Feb 2025₹18.6t₹3.9t₹561.5b27.6x33.1x4.8x
Thu, 23 Jan 2025₹20.1t₹3.8t₹527.4b32.8x38.1x5.3x
Sat, 21 Dec 2024₹20.7t₹3.8t₹526.7b33.6x39.3x5.4x
Mon, 18 Nov 2024₹20.2t₹3.8t₹525.4b32.7x38.4x5.3x
Wed, 16 Oct 2024₹21.7t₹3.7t₹492.6b41.7x44.1x5.8x
Fri, 13 Sep 2024₹21.6t₹3.7t₹492.6b43x43.9x5.8x
Sun, 11 Aug 2024₹20.4t₹3.7t₹482.4b37.2x42.2x5.4x
Tue, 09 Jul 2024₹18.1t₹3.6t₹448.3b34.8x40.5x5.1x
Thu, 06 Jun 2024₹17.1t₹3.6t₹450.9b32x37.9x4.8x
Sat, 04 May 2024₹17.1t₹3.5t₹419.0b34.1x40.9x4.9x
Mon, 01 Apr 2024₹17.0t₹3.5t₹418.9b32.1x40.6x4.9x
Wed, 28 Feb 2024₹17.1t₹3.5t₹418.7b34.7x40.8x4.9x
Fri, 26 Jan 2024₹15.8t₹3.4t₹396.1b34.6x39.8x4.7x
Sun, 24 Dec 2023₹14.6t₹3.4t₹395.2b32.2x37x4.3x
Tue, 21 Nov 2023₹14.0t₹3.4t₹395.1b30.4x35.4x4.1x
Thu, 19 Oct 2023₹13.3t₹3.3t₹369.9b30.2x35.8x4x
Sat, 16 Sep 2023₹13.3t₹3.3t₹369.5b30.4x35.9x4.1x
Mon, 14 Aug 2023₹13.1t₹3.3t₹367.5b29.3x35.6x4x
Wed, 12 Jul 2023₹11.9t₹3.2t₹342.4b25.8x34.6x3.8x
Price to Earnings Ratio

34.6x


Total Market Cap: ₹11.9tTotal Earnings: ₹342.4bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market0.95%
Healthcare3.02%
Pharma3.25%
Pharma3.25%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.90k2.3%
+₹100.8b		13.6%PE39.8x
500420 Torrent Pharmaceuticals₹4.77k5.5%
+₹83.7b		41.5%PE74.6x
500257 Lupin₹2.48k5.7%
+₹61.2b		25.3%PE21.2x
LAURUSLABS Laurus Labs₹1.54k6.4%
+₹49.8b		98.8%PE93.7x
IPCALAB Ipca Laboratories₹1.78k9.9%
+₹40.7b		25.0%PE39.6x

Latest News

WOCKPHARMA
₹1,938.50
Wockhardt
7D
-1.4%
1Y
12.4%
IPCALAB
₹1,778.90
Ipca Laboratories
7D
9.9%
1Y
25.0%
Narrative Update • Jul 03

IPCALAB: Lower Margin Outlook Will Pressure Upcoming Results And Dividend Decision

Analysts have adjusted their price target for Ipca Laboratories to ₹1,517.62 from ₹1,415.37, reflecting updated assumptions for slightly lower revenue growth, a reduced profit margin, and a lower future P/E multiple. What’s in the News for Ipca Laboratories Board meeting scheduled for May 29, 2026 to consider standalone and consolidated audited financial results for the fourth quarter and full financial year ended March 31, 2026.
COHANCE
₹454.50
Cohance Lifesciences
7D
-0.8%
1Y
-56.2%
Narrative Update • Jul 03

COHANCE: Leadership Turnover And Lower Margin Outlook Will Pressure Future Returns

Analysts have cut their price target fair value for Cohance Lifesciences from ₹640 to ₹300, citing updated assumptions for revenue growth, profit margins, and future P/E expectations. What's in the News Cohance Lifesciences scheduled a board meeting on April 27, 2026 to take note of the resignation of the Executive Chairman and Director, consider the appointment of Umang Vohra as Additional Director and Chairman and Group Chief Executive Officer, and review the Cohance Lifesciences Limited Employee Stock Option Plan, 2026.
LAURUSLABS
₹1,542.30
Laurus Labs
7D
6.4%
1Y
98.8%
Narrative Update • Jul 02

LAURUSLABS: Currency And Execution Risks Will Continue To Restrain Margin Upside

Analysts have revised their fair value estimate for Laurus Labs to ₹606.49 from ₹543.09, citing updated assumptions around revenue growth, profit margins, and a slightly higher future P/E multiple. What’s in the News for Laurus Labs Laurus Labs has scheduled a board meeting on April 30, 2026, at 14:00 IST to consider audited financial results for the quarter and year ended March 31, 2026, along with several corporate actions.
526953
₹1,712.80
Venus Remedies
7D
-12.0%
1Y
283.1%
RUBICON
₹1,307.00
Rubicon Research
7D
-7.7%
1Y
n/a
SUNPHARMA
₹1,904.80
Sun Pharmaceutical Industries
7D
2.3%
1Y
13.6%
CONCORDBIO
₹1,274.90
Concord Biotech
7D
-0.9%
1Y
-26.6%
New Narrative • Jun 29

Injectable Capacity And Diversified Platforms Will Drive Strong Long-Term Potential

Catalysts About Concord Biotech Concord Biotech is a fermentation based biopharma company focused on active pharmaceutical ingredients and formulations in areas such as immunosuppressants, anti infectives and oncology. What are the underlying business or industry changes driving this perspective?
500257
₹2,476.10
Lupin
7D
5.7%
1Y
25.3%
AUROPHARMA
₹1,620.50
Aurobindo Pharma
7D
4.2%
1Y
36.0%
500420
₹4,765.60
Torrent Pharmaceuticals
7D
5.5%
1Y
41.5%
Narrative Update • Jun 25

500420: Dividend Payouts And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their fair value estimate for Torrent Pharmaceuticals steady at about ₹4,878.79 per share, citing unchanged assumptions for revenue growth, profit margins, discount rate, and future P/E multiple. What's in the News for Torrent Pharmaceuticals At its AGM on 23 June 2026, Torrent Pharmaceuticals declared a final dividend of ₹9.00 per equity share of face value ₹5.00 for the financial year ended 31 March 2026.
ACUTAAS
₹3,694.80
Acutaas Chemicals
7D
12.0%
1Y
229.3%
Narrative Update • Jun 24

ACUTAAS: Rich Future P E And Dividend Plans Will Pressure Returns

Analysts have trimmed their fair value estimate for Acutaas Chemicals, with the price target moving from ₹2,486.33 to ₹2,390.78. This reflects updated assumptions around future P/E while keeping growth and margin expectations broadly unchanged.
EMCURE
₹1,839.10
Emcure Pharmaceuticals
7D
-2.2%
1Y
46.9%
Narrative Update • Jun 23

EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook

Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.
ERIS
₹1,431.10
Eris Lifesciences
7D
-1.9%
1Y
-16.1%
Narrative Update • Jun 22

ERIS: Stable Outlook And Upcoming Board Decisions Will Drive Future Upside

Analysts have kept their fair value estimate for Eris Lifesciences steady at ₹1,696.60, with only minor model adjustments to profit margin assumptions and forward P/E inputs informing this unchanged price target. What’s in the News for Eris Lifesciences Eris Lifesciences has scheduled a board meeting on May 20, 2026 to consider and approve standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026.
ZYDUSLIFE
₹1,140.60
Zydus Lifesciences
7D
3.6%
1Y
13.9%
Narrative Update • Jun 17

ZYDUSLIFE: Buyback, Rare Disease Expansion And USFDA Updates Will Guide Share Outlook

The latest Narrative Update on Zydus Lifesciences keeps the analyst fair value estimate steady at ₹1,066.50, with unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. Analysts view the existing price target framework as still appropriately reflecting the stock's current risk and return trade off.
506820
₹8,297.90
AstraZeneca Pharma India
7D
-1.0%
1Y
-8.7%